Pre-clinical evaluation of Cinobufotalin (cas 1108-68-5) as a potential anti-lung cancer agent

Add time:08/12/2019    Source:sciencedirect.com

Lung cancer is a major cause of cancer-related mortality in the United States and around the world. Due to the pre-existing or acquired chemo-resistance, the current standard chemotherapy regimens only show moderate activity against lung cancer. In the current study, we explored the potential anti-lung cancer activity of Cinobufotalin (cas 1108-68-5) in vivo and in vitro, and studied the underlying mechanisms. We demonstrated that cinobufotalin displayed considerable cytotoxicity against lung cancer cells (A549, H460 and HTB-58 lines) without inducing significant cell apoptosis. Our data suggest that mitochondrial protein cyclophilin D (Cyp-D)-dependent mitochondrial permeability transition pore (mPTP) opening mediates cinobufotalin-induced non-apoptotic death of lung cancer cells. The Cyp-D inhibitor cyclosporine A (CsA), the mPTP blocker sanglifehrin A (SfA), and Cyp-D shRNA-silencing significantly inhibited cinobufotalin-induced mitochondrial membrane potential (MMP) reduction and A549 cell death (but not apoptosis). Using a mice xenograft model, we found that cinobufotalin inhibited A549 lung cancer cell growth in vivo. Thus, cinobufotalin mainly induces Cyp-D-dependent non-apoptotic death in cultured lung cancer cells. The results of this study suggest that cinobufotalin might be further investigated as a novel anti-lung cancer agent.

We also recommend Trading Suppliers and Manufacturers of Cinobufotalin (cas 1108-68-5). Pls Click Website Link as below: cas 1108-68-5 suppliers

Prev:Elucidation of the opening of the epoxidic ring of the 3β-acetoxy-14α,15α-epoxy-5α-cholest-8-en-7-one by methanol, using NMR techniques assisted by a conformational study through theoretical calculations
Next:Microbial transformation of Cinobufotalin (cas 1108-68-5) by Alternaria alternate AS 3.4578 and Aspergillus niger AS 3.739)